Kala Pharmaceuticals Inc (OQ:KALA)

Business Focus: Bio Therapeutic Drugs

Nov 08, 2018 07:30 ET
Kala Pharmaceuticals Reports Third Quarter 2018 Financial Results
Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today reported financial results for the third quarter ended September 30, 2018.
Nov 07, 2018 16:05 ET
Kala Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the Jefferies 2018 London Healthcare Conference in London, U.K.. Todd Bazemore, Chief Operating Officer at Kala Pharmaceuticals, will provide a corporate overview on Wednesday, November 14, 2018 at 2:00 PM GMT.
Oct 25, 2018 08:00 ET
Kala Pharmaceuticals Appoints Steven Zhang as Vice President of Medical Affairs
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced the appointment of Steven Zhang, M.D., Ph.D., as Vice President of Medical Affairs
Oct 24, 2018 08:55 ET
New Research Coverage Highlights Vmware, Kala Pharmaceuticals, El Pollo Loco, Integer, AAC, and Vectren — Consolidated Revenues, Company Growth, and Expectations for 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Vmware, Inc. (NYSE:VMW), Kala Pharmaceuticals, Inc. (NASDAQ:KALA), El...
Oct 19, 2018 16:05 ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Oct 18, 2018 08:00 ET
Kala Pharmaceuticals to Present at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting and at the Ophthalmology Innovation Summit at AAO
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that it will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) meeting taking place on October 25, 2018. Data from a Phase 3 clinical trial conducted with KPI-121 0.25% for the short-term treatment of dry eye disease an
Oct 16, 2018 08:00 ET
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease
Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for KPI-121 0.25%, a topical product candidate which, if approved, could be the first FDA-approved product for the temporary relief of signs and symptoms of dry eye disease.
Oct 11, 2018 16:01 ET
Kala Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, announced today that the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 1,125,000 shares of common stock at the public offering price of $8.25 per share, less underwriting discounts. After giving effect to the option closing, the total number of shares sold by Kala in
Oct 03, 2018 08:00 ET
Kala Pharmaceuticals Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock
Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, announced today the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.25 per share, before offering discounts. The offering will result in aggregate gross proceeds of approximately $61.9 million to Kala, before deducting underwriting discounts and offering expenses. Kala al
Oct 02, 2018 16:18 ET
Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Million
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced the closing of Kala’s $110 million credit facility with funds managed by Athyrium Capital Management, LP, a leading healthcare focused investment firm.
Oct 02, 2018 16:18 ET
Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock
Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, announced today that it has commenced an underwritten public offering of 7,500,000 shares of its common stock. Kala also intends to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,125,000 shares of common stock offered in the public offering at the public offering price, less the
Sep 21, 2018 16:05 ET
Kala Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Aug 31, 2018 07:50 ET
Research Report Identifies Holly Energy Partners, First Merchants, Enbridge Energy Management, Activision Blizzard, Coherus BioSciences, and Kala Pharmaceuticals with Renewed Outlook — Fundamental Ana
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Holly Energy Partners, L.P. (NYSE:HEP), First Merchants Corporation...
Aug 29, 2018 16:01 ET
Kala Pharmaceuticals to Present at Upcoming Investor Conferences
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that members of its management team will participate in the following upcoming conferences:
Aug 23, 2018 13:46 ET
Kala Pharmaceuticals Announces FDA Approval of INVELTYS™ for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that the U.S. Food and Drug Administration (FDA) has approved INVELTYSTM (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. INVELTYS is the first twice-daily (BID) ocular corticosteroid approved for this indication.
Aug 09, 2018 07:00 ET
Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapies using its proprietary mucus-penetrating particle (MPP) technology with an initial focus on the treatment of eye diseases, today reported financial results for the second quarter ended June 30, 2018.
Aug 08, 2018 16:05 ET
Kala Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will present at the 2018 Wedbush PacGrow Healthcare Conference in New York, NY. Mark Iwicki, Chairman and Chief Executive Officer at Kala Pharmaceuticals, will provide a corporate overview on Wednesday, August 15, 2018 at 9:45 AM ET.
Jul 31, 2018 08:00 ET
Kala Pharmaceuticals Announces Dosing of First Patient in Phase 3 STRIDE 3 Trial of KPI-121 0.25% in Patients with Dry Eye Disease
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that the first patient has been dosed in STRIDE 3 (Short Term Relief In Dry Eye), its Phase 3 trial of KPI-121 0.25% for the short-term treatment of dry eye disease.
Jul 27, 2018 07:55 ET
Recent Analysis Shows Kala Pharmaceuticals, Integer, Carnival, Coty, Sykes Enterprises, and Agilent Technologies Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kala Pharmaceuticals, Inc. (NASDAQ:KALA), Integer Holdings Corporation...
Jun 19, 2018 16:01 ET
Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Plan
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today provided an update on the development plan for KPI-121 0.25%, which if approved could be the first FDA-approved product for the short-term treatment of dry eye disease.
May 22, 2018 07:55 ET
Market Trends Toward New Normal in Meredith, Weis Markets, Kala Pharmaceuticals, Fortress Transportation and Infrastructure Investors, Kraton, and Web.com Group — Emerging Consolidated Expectations, A
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Meredith Corporation (NYSE:MDP), Weis Markets, Inc. (NYSE:WMK), Kala...
May 10, 2018 07:00 ET
Kala Pharmaceuticals Reports First Quarter 2018 Financial Results
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology with an initial focus on the treatment of eye diseases, today reported financial results for the quarter ended March 31, 2018.
May 09, 2018 17:05 ET
Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launch
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced the following key commercial hires in preparation for the potential approval and launch of INVELTYSTM, a twice-daily steroid eye drop in development for the treatment of inflammation and pain following ocular surgery:
May 08, 2018 08:00 ET
Kala Pharmaceuticals to Present at Upcoming Investor Conferences
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that Mark Iwicki, Chairman and Chief Executive Officer, will provide a corporate overview at the Bank of America Merrill Lynch 2018 Health Care Conference and the Jefferies 2018 Global Healthcare Conference. Details of the presentations are as follows:
Apr 09, 2018 16:05 ET
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that in connection with the appointment of Eric Trachtenberg as General Counsel and Corporate Secretary, the Company granted Mr. Trachtenberg an inducement award outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Apr 09, 2018 08:00 ET
Kala Pharmaceuticals to Present at the 2018 American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) and at the Ophthalmology Innovation Summit at ASCRS
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will be presenting at the Spotlight on Dry Eye session at the Ophthalmology Innovation Summit at the American Society of Cataract and Refractive Surgery Annual Meeting (OIS@ASCRS) taking place on April 12, 2018. Data from the Phase 3 clinical trials conducted with INVELTYS™ (KPI-121 1%), a topical twice-a-day product
Apr 03, 2018 08:00 ET
Kala Pharmaceuticals Appoints Eric Trachtenberg as General Counsel and Corporate Secretary
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced the appointment of Eric Trachtenberg as General Counsel and Corporate Secretary.
Mar 28, 2018 08:10 ET
Recent Analysis Shows Welltower, Integer, Jernigan Capital, ZTO EXPRESS INC, Kala Pharmaceuticals, and Covenant Transportation Group Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Welltower Inc. (NYSE:WELL), Integer Holdings Corporation...
Mar 26, 2018 07:00 ET
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today reported financial results for the fourth quarter and full year 2017.
Mar 19, 2018 08:00 ET
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will release fourth quarter and full year 2017 financial results on Monday, March 26, 2018. Kala will host a live conference call and webcast at 8:00 AM ET to provide a general business update and discuss the Company’s 2017 financial results.
Mar 14, 2018 08:00 ET
Kala Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will present at the Oppenheimer 28th Annual Healthcare Conference in New York, NY. Todd Bazemore, Chief Operating Officer at Kala Pharmaceuticals, will provide a corporate overview on Wednesday, March 21, 2018 at 10:55 AM ET.
Mar 05, 2018 08:00 ET
Kala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee Chair
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced the appointment of Gregory Perry to the Company’s Board of Directors and Chair of its Audit Committee.
Jan 25, 2018 08:10 ET
New Research: Key Drivers of Growth for Comstock Resources, Varonis, Union Bankshares, Heidrick & Struggles International, Tejon Ranch, and Kala Pharmaceuticals — Factors of Influence, Major Initiativ
NEW YORK, Jan. 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Comstock Resources, Inc. (NYSE:CRK), Varonis Systems,...
Jan 05, 2018 07:00 ET
Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced topline results from its two Phase 3 clinical trials, STRIDE 1 and STRIDE 2 (STRIDE - Short Term Relief In Dry Eye), evaluating the safety and efficacy of KPI-121 0.25% versus placebo in patients with dry eye disease.
Jan 05, 2018 06:50 ET
Kala Pharmaceuticals Announces New Drug Application for INVELTYSTM (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that the New Drug Application (NDA) for INVELTYSTM (KPI-121 1%), a topical twice-a-day product candidate for the treatment of inflammation and pain in patients who have undergone ocular surgery, has been accepted for review by the United States Food and Drug Administration (FDA). The FDA, in its 74-day letter, indi
Nov 13, 2017 08:00 ET
Kala Pharmaceuticals Appoints Todd Bazemore as Chief Operating Officer
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced the appointment of Todd Bazemore as Chief Operating Officer of the Company. He will report directly to Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals and is expected to join Kala on November 20, 2017.
Nov 07, 2017 07:30 ET
Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today reported financial results for the third quarter and nine months ended September 30, 2017 and provided an update on business progress.
Oct 25, 2017 08:00 ET
Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYSTM (KPI-121 1%)
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for INVELTYSTM (KPI-121 1%), a topical twice-a-day product candidate for the treatment of inflammation and pain in patients who have undergone ocular surgery. If approved, Kala expects INVELTYS would be the first twice-daily ocular corticosteroid indicated for the treatment of post-operative ocular inflammation and pain. The brand name for KPI-121 1%, INVELTYS, has been